Subscribe to our newsletter.
Copyright 2024 © All rights Reserved Goffin Molecular Technologies
The ViennaLab Hereditary Cancer NGS Assay is a comprehensive diagnostic tool designed to identify individuals at high risk for hereditary cancers. Utilizing Next-Generation Sequencing technology, the assay covers 31 critical genes associated with various types of hereditary cancers. It detects a range of variants including SNVs, InDels, and CNVs. The kit comes complete with library preparation components and proprietary bioinformatic analysis software, GENOVESA, for streamlined variant interpretation. This all-encompassing solution offers clinicians valuable insights to inform genetic counseling and personalized surveillance plans, elevating the standard of care in oncology.
Instructions for Use
Brochure NGS Assays
For any missing information or if you require additional details, please do not hesitate to contact us.
In the rapidly evolving landscape of oncology, early and accurate detection of somatic mutations is pivotal for effective cancer management. ViennaLab’s Hereditary NGS Assay is designed to meet this challenge head-on, serving as a state-of-the-art tool for comprehensive analysis of cancer-associated genes.
The Hereditary Cancer NGS Assay covers a substantial list of the most relevant cancer-associated genes include:
aPc, atm, bard1, bLm, bmPr1a, brca1, brca2, briP1, cdH1, cdK4, cdKn2a, cHeK2, ePcam, mLH1, mre11a, msH2, msH6, mUtyH, nbn, PaLb2, Pms2, Prss1, Pten, rad50, rad51c, rad51d, sLX4, smad4, stK11, tP53, vHL
This extensive scope allows for the detection of a wide range of somatic mutations, thereby providing a more complete understanding of the genetic factors driving the disease.
The assay is designed to identify Single Nucleotide Variants (SNVs), insertions and deletions (InDels), and CNV, offering a multi-faceted genetic view. The targeted regions include the whole Coding Sequence (CDS) region and hotspot introns for fusions, covering a target size of 62 Kb.
The assay comes with integrated bioinformatic analysis using the Genovesa software. This helps in streamlining the complex process of data interpretation, transforming raw sequencing data into a clinically actionable genetic report.
The assay serves as a crucial tool in the realm of personalized oncology, offering a comprehensive and targeted approach to genetic testing. This enables clinicians to tailor treatment plans to individual patient profiles, taking into account specific somatic mutations that may influence drug response or resistance.
The ViennaLab Hereditary Cancer NGS Assay is an invaluable tool for modern oncology, enabling the precise identification of a broad array of gene mutations associated with cancer. With its comprehensive target gene list, integrated bioinformatics, and exceptional support material, the assay stands as a pivotal resource for clinicians and researchers alike, aiming to drive forward the capabilities of personalized medicine in cancer diagnostics.
Subscribe to our newsletter.